Globus Medical Inc.'s stock plummeted 22.96% after its Q1 2025 earnings call, driven by a disappointing revenue performance, lowered EPS guidance, and ongoing integration challenges. The company reported a 1.4% year-over-year revenue decline to $598.1 million, missing expectations due to a 30.6% drop in enabling technology sales, supply chain disruptions from the NuVasive merger, and reimbursement headwinds in biologics and neuromonitoring. Non-GAAP EPS guidance was cut by $0.10 to $3.00-$3.30, reflecting costs from the early Nevro acquisition, which raised concerns about execution risks amidst unresolved NuVasive integration issues. Despite management’s optimism for a Q2 recovery and a robust deal pipeline, investor confidence was shaken by these near-term setbacks and market uncertainties, triggering a sharp sell-off.
The stock of Globus Medical Inc (GMED) dropped significantly by 22.96% following the Q1 2025 earnings call due to several factors highlighted in the transcript that likely contributed to investor concerns.
Below is an analysis of the key reasons:
Disappointing Revenue Performance:
Flat Revenue Growth: Globus reported a slight revenue decline of 1.4% year-over-ye...
